EQ
Equillium, Inc.
Healthcare · Biotechnology · NCM
$2.94
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 57.1%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$138M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-8.42
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
-54.4%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$6.38
+117% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 8 analysts covering this stock
About Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

https://www.equilliumbio.com

Country: United States Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.5% PASS
Debt must be below 33% of total assets
Cash Ratio
20.2% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.803
Good returns relative to risk taken
Kelly Fraction
-0.0102
No positive edge detected — the data suggests staying out
Calmar Ratio
0.326
Drawdown risk outweighs the returns — higher risk profile
Annual Return
26.3%
Historical annualised return based on price data
Max Drawdown
-80.7%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
7
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
N/A
52W High
$2.70
-9% below the year high
52W Low
$0.27
989% above the year low
Avg Volume
429,346
Average daily shares traded — higher means easier to buy and sell
Short Ratio
7.2
Days it would take all short sellers to cover — higher means more crowded
Short % Float
5.2%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.39
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.01
Conservative use of debt — low financial risk
Current Ratio
18.62
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
18.33
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-12,542,750
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-19,055,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
8
Target High
$12.00
Target Median
$6.38
Target Low
$1.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-03-13 ZEDELMAYER CHRISTINE Chief Operating Officer 120,312 $300,816
2026-03-13 ZEDELMAYER CHRISTINE Chief Operating Officer 120,312 $94,445
2026-03-09 ZEDELMAYER CHRISTINE Chief Operating Officer 181,219 $362,438
2026-03-09 ZEDELMAYER CHRISTINE Chief Operating Officer 152,361 $119,603
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer 185,937 $328,104
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer 185,937 $328,104
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer 185,937 $141,750
2026-02-19 ZEDELMAYER CHRISTINE Chief Operating Officer 185,937 $141,750
2026-01-08 TOM PENNY Officer 6,533 $8,428
2025-12-23 ZEDELMAYER CHRISTINE Chief Operating Officer 100,000 $150,000
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Sale 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.